Bristol-myers Squibb Compnay

Bristol Meyers Squibb Company

Nenghui Wang

Richard Eric Olson

John E Macor

Ivar M McDonald

Dalton King

F Christopher Zusi

James H Cook, Ii

Christiana I Iwuagwu

Robert A Mate

Haiquan Fang

Matthew D Hill

Andrew Charles Good

Thomas P Maduskuie, Jr

Yong-Jin Wu

Lorin Andrew Thompson

Lawrence R Marcin

Andrew J Tebben

Wei Deng

Hong Liu

Dmitry S Zuev

Rex Denton

Kimberley A Lentz

James H Cook Ii

James H Ii Cook

Christopher F Zusi

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic &#x3b1;7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands

The disclosure generally relates to compounds of the following formula, including their salts, as well as compositions and methods of using the compounds. The compounds are prodrugs for ligands, agonists, and partial agonists for the nicotinic &#x3b1;7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs

Quinuclidine compounds as &#x3b1;-7 nicotinic acetylcholine receptor ligands

The disclosure provides compounds of formula I, including Ia, Ib, Ic, or Id, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic &#x3b1;7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands

Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands

There is provided a series of macrocyclic diaminopropanes of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R, R, R, m, n, W, X, Y, Z and L as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by &#x3b2;-secretase and, more specifically, inhibit the production of A&#x3b2;-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to &#x3b2;-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

Diaminopropane derived macrocycles as inhibitors of &#x3b2; amyloid production

This invention relates to novel carbocycles and heterocycles having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

Succinoylamino carbocycles and heterocycles as inhibitors of a-&bgr; protein production

Growing community of inventors

Guilford, CT, United States of America

Nenghui Wang